
Opinion|Videos|January 31, 2025
Faricimab Molecular Design and Role of Ang-2
Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases?
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
5























